Julia Gregory
Director/Board Member chez BIOHAVEN LTD.
Fortune : 1 M $ au 31/03/2024
Profil
Julia Paige Gregory is currently the Chairman & Chief Executive Officer at Isometry Advisors, Inc., the Director at Iconic Therapeutics, Inc., the Independent Director at Nurix Therapeutics, Inc., the Managing Director at M.M.
Dillon & Co. LLC, the Director at Freeline Therapeutics Ltd., and the Independent Director at Biohaven Ltd.
Previously, she held positions such as President, Chief Executive Officer & Director at Five Prime Therapeutics, Inc., President, Chief Executive Officer & Director at ContraFect Corp., Executive Chairman at Cavion, Inc., Director at Global Alliance for TB Drug Development, Director at Clinipace, Inc., Independent Outside Director at Nxera Pharma Co., Ltd., Non-Executive Director at Kuur Therapeutics Ltd., Independent Director at IMV, Inc., and Independent Director at Biohaven Pharmaceutical Holding Co. Ltd.
She also served as the CFO & Executive VP-Corporate Development at Lexicon Pharmaceuticals, Inc., Head-Investment Banking & Life Sciences Practice at Punk Ziegel & Co., and Investment Banker at Dillon, Read & Co., Inc. Ms. Gregory holds an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from Elliott School of International Affairs.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOHAVEN LTD.
0,03% | 30/04/2024 | 25 665 ( 0,03% ) | 1 M $ | 31/03/2024 |
NURIX THERAPEUTICS, INC.
-.--% | 21/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
IMV INC.
-.--% | 04/01/2023 | 0 ( -.--% ) | - $ | 31/12/2023 |
Postes actifs de Julia Gregory
| Sociétés | Poste | Début |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Director/Board Member | 01/08/2019 |
| BIOHAVEN LTD. | Director/Board Member | 28/09/2022 |
Isometry Advisors, Inc.
 Isometry Advisors, Inc. Miscellaneous Commercial ServicesCommercial Services Isometry Advisors, Inc. is a biotechnology financial and management advisory firm. Julia Paige Gregory has been the CEO of the American company since 2016. | Chief Executive Officer | 01/04/2016 |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
M.M. Dillon & Co. LLC
 M.M. Dillon & Co. LLC Investment Banks/BrokersFinance M.M. Dillon & Co. operates as an investment banking firm. It offers capital raising and advisory services across all forms of securities. The firm also provides mergers and acquisition, capital raising, private placement, capital restructuring, public equity offering, and transaction advisory services. It provides services to the healthcare, technology, media & telecom, industrial, energy, clean tech and gaming industries. The company was founded by George W. Bickerstaff III in 2009 and is headquartered in Greenwich, CT. | Corporate Officer/Principal | 01/06/2018 |
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Director/Board Member | 01/04/2017 |
Anciens postes connus de Julia Gregory
| Sociétés | Poste | Fin |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Director/Board Member | 20/02/2024 |
| IMV INC. | Director/Board Member | 08/01/2023 |
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | 03/10/2022 |
| ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Julia Gregory
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Elliott School of International Affairs | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| NXERA PHARMA CO., LTD. | Health Technology |
| CONTRAFECT CORPORATION | Health Technology |
| IMV INC. | Health Technology |
| BIOHAVEN LTD. | Health Technology |
| Entreprise privées | 14 |
|---|---|
Punk Ziegel & Co.
 Punk Ziegel & Co. Investment Banks/BrokersFinance Located in New York City, Punk, Ziegel & Co. is a specialty investment bank providing a full range of research, equity market making and corporate finance services focusing on high growth sectors within the healthcare technology, biotechnology and life sciences industries. Punk, Ziegel's, in-depth securities analysis begins with the identification of high-growth industries and timely investment ideas before they have been fully exploited by the investment community. Within these industry niches, their analysts pinpoint companies offering leadership potential and maximum investment opportunities. Issue-oriented, in-depth analysis is then generated on a continuing basis to insure that their investment and corporate finance advice remains accurate and up-to-date. | Finance |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
Clinipace, Inc.
 Clinipace, Inc. Miscellaneous Commercial ServicesCommercial Services Clinipace, Inc. provides digital contract research solutions. The firm operates as a digital contract research organization that assists life science firms in developing and executing regulatory strategies, clinical development, and post-approval research. Its service areas encompass clinical monitoring, data management, medical affairs and writing, patient recruitment, study feasibility, and site selection and management. The company was founded by Ronald G. Marks, Christopher K. Porter, and Jeff Lewis Williams in 2003 and is headquartered in Morrisville, NC. | Commercial Services |
Cavion, Inc.
 Cavion, Inc. Pharmaceuticals: MajorHealth Technology Cavion, Inc. engages in development of pharmaceuticals products. It produces oncology drugs to treat solid tumors that selectively inhibits the t-type calcium channel. The company was founded by Andrew J. Krouse, Lloyd S. Gray, and Timothy L. Macdonald in 2005 and is headquartered in Charlottesville, VA. | Health Technology |
| Dillon, Read & Co., Inc. | Finance |
| The Institute for the Study of Aging, Inc. | |
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Health Technology |
M.M. Dillon & Co. LLC
M.M. Dillon & Co. LLC Investment Banks/BrokersFinance M.M. Dillon & Co. operates as an investment banking firm. It offers capital raising and advisory services across all forms of securities. The firm also provides mergers and acquisition, capital raising, private placement, capital restructuring, public equity offering, and transaction advisory services. It provides services to the healthcare, technology, media & telecom, industrial, energy, clean tech and gaming industries. The company was founded by George W. Bickerstaff III in 2009 and is headquartered in Greenwich, CT. | Finance |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Isometry Advisors, Inc.
Isometry Advisors, Inc. Miscellaneous Commercial ServicesCommercial Services Isometry Advisors, Inc. is a biotechnology financial and management advisory firm. Julia Paige Gregory has been the CEO of the American company since 2016. | Commercial Services |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
